Nanoformulation of synergistic TLR ligands to enhance vaccination against Entamoeba histolytica.
about
TLR Agonists as Adjuvants for Cancer Vaccines.Liposomal vaccine formulations as prophylactic agents: design considerations for modern vaccines.Toll-like receptors participate in Naegleria fowleri recognition.Adjuvant composition and delivery route shape immune response quality and protective efficacy of a recombinant vaccine for Entamoeba histolytica.
P2860
Nanoformulation of synergistic TLR ligands to enhance vaccination against Entamoeba histolytica.
description
2017 nî lūn-bûn
@nan
2017 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
Nanoformulation of synergistic ...... against Entamoeba histolytica.
@ast
Nanoformulation of synergistic ...... against Entamoeba histolytica.
@en
type
label
Nanoformulation of synergistic ...... against Entamoeba histolytica.
@ast
Nanoformulation of synergistic ...... against Entamoeba histolytica.
@en
prefLabel
Nanoformulation of synergistic ...... against Entamoeba histolytica.
@ast
Nanoformulation of synergistic ...... against Entamoeba histolytica.
@en
P2093
P2860
P1433
P1476
Nanoformulation of synergistic ...... against Entamoeba histolytica.
@en
P2093
Christopher B Fox
James Elvecrog
Mark A Tomai
Mayuresh M Abhyankar
P2860
P304
P356
10.1016/J.VACCINE.2016.12.057
P407
P577
2017-01-12T00:00:00Z